Edwards Lifesciences
EW · New York Stock Exchange · Health Care
☆ Follow
Shareholder advocacy aimed at Edwards Lifesciences
Nothing recorded yet. That means no campaign in our database names this company, not that none exists.
What shareholders voted on
From Edwards Lifesciences’s own filings with the SEC. Support is the share of votes cast for and against, so abstentions and broker non-votes are not counted in it.
2026
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| David T. Feinberg, MD | Company proposal | 99.6% | Passed | |
| The approval of the Company’s Amended and Restated Long-Term Stock Incentive Compensation Program | Company proposal | 96% | Passed | |
| Company’s named executive officer compensation | Company proposal | 89.3% | Passed | |
| Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 | Auditor | 88.7% | Passed | |
| Election of Ramona Sequeira | Director | 99.7% | Passed | |
| Election of Leslie C. Davis | Director | 97.2% | Passed | |
| Election of Bernard J. Zovighian | Director | 96.6% | Passed | |
| Election of Kieran T. Gallahue | Director | 96.1% | Passed | |
| Election of Leslie S. Heisz | Director | 95.7% | Passed | |
| Election of Steven R. Loranger | Director | 93.9% | Passed | |
| Election of Nicholas J. Valeriani | Director | 92.8% | Passed | |
| Election of Paul A. LaViolette | Director | 90.4% | Passed |
2022
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| The advisory stockholder proposal to reduce the share ownership threshold to call a special meeting | Shareholder proposal | a) Long-Term Stock Program | 36.6% | Failed |
| Company’s named executive officer compensation | Company proposal | 90% | Passed | |
| Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 | Auditor | 94% | Passed | |
| Election of Ramona Sequeira | Director | 99.1% | Passed | |
| Election of Steven R. Loranger | Director | 99.1% | Passed | |
| Election of Kieran T. Gallahue | Director | 99.1% | Passed | |
| Election of Leslie H. Heisz | Director | 98.7% | Passed | |
| Election of Martha H. Marsh | Director | 97.7% | Passed | |
| Election of Paul A. LaViolette | Director | 97.4% | Passed | |
| Election of Michael A. Mussallem | Director | 94.6% | Passed | |
| Election of Nicholas J. Valeriani | Director | 87.5% | Passed |
2020
2019
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| The non-binding advisory stockholder proposal regarding independent chair policy | Shareholder proposal | a) Long-Term Stock Program | 22% | Failed |
| Wesley W. von Schack | Company proposal | 99.4% | Passed | |
| William J. Link, Ph.D | Company proposal | 96.2% | Passed | |
| Compensation of Edwards’ named executive officers | Company proposal | 95.1% | Passed | |
| Ratification of the selection of PricewaterhouseCoopers LLP as Edwards’ independent registered public accounting firm for the fiscal year ending December 31, 2019 | Auditor | 97.5% | Passed | |
| Election of Leslie S. Heisz | Director | 99.5% | Passed | |
| Election of Kieran T. Gallahue | Director | 99.5% | Passed | |
| Election of Martha H. Marsh | Director | 98.3% | Passed | |
| Election of Nicholas J. Valeriani | Director | 98% | Passed | |
| Election of Steven R. Loranger | Director | 98% | Passed | |
| Election of Michael A. Mussallem | Director | 96.4% | Passed |
2018
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| The non-binding advisory stockholder proposal regarding action by written consent | Shareholder proposal | a) Long-Term Stock Program | 23.7% | Failed |
| Wesley W. von Schack | Company proposal | 99.2% | Passed | |
| William J. Link, Ph.D | Company proposal | 96.8% | Passed | |
| Compensation of Edwards’ named executive officers | Company proposal | 94.6% | Passed | |
| Ratification of the selection of PricewaterhouseCoopers LLP as Edwards’ independent public accountants for the fiscal year ending December 31, 2018 | Auditor | 97.7% | Passed | |
| Election of Kieran T. Gallahue | Director | 99.1% | Passed | |
| Election of Leslie S. Heisz | Director | 98.8% | Passed | |
| Election of Martha H. Marsh | Director | 98.1% | Passed | |
| Election of Nicholas J. Valeriani | Director | 98% | Passed | |
| Election of Steven R. Loranger | Director | 97.8% | Passed | |
| Election of Michael A. Mussallem | Director | 96.5% | Passed |
Proxy statements and vote results
Straight from Edwards Lifesciences’s own SEC filings. The proxy statement lists what shareholders were asked to vote on; the 8-K certifies how the vote went.
| Year | Filing | Filed |
|---|---|---|
| 2026 | Vote results | 2026-05-08 |
| 2026 | Proxy statement | 2026-03-26 |
| 2025 | Vote results | 2025-05-08 |
| 2025 | Proxy statement | 2025-03-26 |
| 2024 | Vote results | 2024-05-08 |
| 2024 | Proxy statement | 2024-03-26 |
| 2023 | Vote results | 2023-05-15 |
| 2023 | Proxy statement | 2023-03-28 |
| 2022 | Vote results | 2022-05-04 |
| 2022 | Proxy statement | 2022-03-22 |
| 2021 | Vote results | 2021-05-05 |
| 2021 | Proxy statement | 2021-03-23 |
| 2020 | Vote results | 2020-05-08 |
| 2020 | Proxy statement | 2020-03-25 |
| 2019 | Vote results | 2019-05-08 |
| 2019 | Proxy statement | 2019-03-27 |
| 2018 | Vote results | 2018-05-21 |
| 2018 | Proxy statement | 2018-03-29 |
Do you represent Edwards Lifesciences? Claim this profile to respond to the campaigns listed here.